Com a expiração da patente do Ozempic em março de 2026, o Brasil deu um passo significativo na democratização do acesso a tratamentos modernos para obesidade: a Anvisa aprovou o Ozivy, primeiro medicamento injetável à base de semaglutida produzido em solo nacional, desenvolvido pela farmacêutica EMS. O evento não é apenas regulatório — é um momento em que a soberania farmacêutica encontra uma demanda de saúde pública crescente, abrindo caminho para que mais brasileiros possam acessar uma classe de medicamentos que redefiniu o tratamento do sobrepeso no mundo.
Folha De Pernambuco
· May 26, 2026
· health
· 1 min de lectura
High
Verificación: Verificado
Brazil's Anvisa approves first domestically-produced GLP-1 weight-loss injection
◉
Health & Medicine
2746 artículos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% coincidencia
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% coincidencia
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% coincidencia
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% coincidencia
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% coincidencia
Cobertura Relacionada
G1 · Aug 20
Pai agradece médicos após morte de gêmeas unidas pela cabeça: 'mais vitórias que derrotas'
Pai das gêmeas unidas pela cabeça que morreram em cirurgia de separação agradece empenho de mais de 50 profissionais do …
Folha de S.Paulo · Aug 20 Selton Mello se emociona ao receber Kikito de Cristal em GramadoSelton Mello recebeu o Kikito de Cristal no Festival de Gramado e se emocionou ao lembrar que era a primeira vez receben…
G1 · Aug 20 CEMEI Amiguinhos da Vila inaugura prédio moderno com capacidade para 320 alunosInaugurado novo prédio do CEMEI Amiguinhos da Vila em Montes Claros, com capacidade para 320 alunos, oito salas de aula,…
Folha de S.Paulo · Aug 20 Hepatites D e E circulam no Brasil e preocupam especialistasRevisão de 200 estudos com dados de 14,5 milhões de pessoas revela que hepatites D e E circulam no Brasil com prevalênci…
Sesgo y Encuadre
⚖
Straightforward reporting of regulatory approval with minimal bias; uses colloquial term 'canetas emagrecedoras' consistently and presents factual information about patent expiration and approval process.
Bias Direction
center
Confidence
HIGH
Neutral informational framing focused on regulatory milestone and procedural details; uses accessible language ('canetas emagrecedoras') that reflects local terminology without editorializing.
canetas emagrecedoras (weight-loss pens) - colloquial but not inherently loaded, reflects common usage
Patient or consumer perspective on drug access/affordability
Healthcare provider commentary on domestic production benefits
Comparison of pricing between domestic and imported versions
Public health implications or concerns about GLP-1 medication use
Industry expert analysis on competitive landscape
Impacto Geopolítico
🌎
Brazil's domestic GLP-1 production capability reduces pharmaceutical import dependency and positions it as a regional generics hub, while challenging Novo Nordisk's market dominance in Latin America.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Global pharmaceutical markets
Brazil strengthens pharmaceutical sovereignty and generic drug manufacturing capacity, reducing reliance on Danish/foreign producers. This enhances Brazil's regional soft power in healthcare and positions it competitively against multinational pharma dominance in emerging markets.
Similar to India's rise as a generic drug manufacturer in the 1990s-2000s, enabling affordable medications across the Global South while challenging patent-holder monopolies.
Lente Económico
📈
Brazil's domestic GLP-1 market expands with Anvisa approval of EMS's Ozivy semaglutide, enabling local production post-Ozempic patent expiration and reducing import dependency.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical manufacturing
Healthcare/Biotechnology
Medical devices
Generic drug production
Healthcare services
Brazilian consumers gain access to more affordable domestically-produced GLP-1 weight-loss treatments, reducing reliance on expensive imported alternatives and potentially lowering medication costs through increased competition as additional variants enter the market.
Demonstrates successful patent expiration transition and regulatory capacity for complex biologics. May incentivize local pharmaceutical R&D investment and generic production. Potential future price regulation discussions as market competition increases with 6+ additional variants under review.